May 7, 2008 Savient Reports Favorable Interim Data from Puricase® Open Label Extension Study April 21, 2008 Savient Provides Update on  Puricase® BLA February 4, 2008 Savient Reports Additional Positive Phase 3 Results for Puricase® December 13, 2007 Savient Press Release - Successful Phase 3 Trials of Puricase® October 16, 2007 Savient Completes Puricase® Phase 3 Study March 6, 2007 Savient Completes Enrollment for Puricase® Phase 3 Study August 4, 2006 Savient Completes Rosemont Sale June 14, 2006 Savient Initiates Patient Dosing for Puricase® Phase 3 Study May 3, 2006 Savient Receives FDA Final Approval for Puricase® March 21, 2006 Savient and FDA Agree on Phase 3 Protocol SPA Puricase® (PEG-uricase) on Track to Enter Phase 3 November 14, 2005 Savient's Puricase® (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients with Treatment Resistant Gout July 28, 2005 Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of Puricase® June 29, 2005 Mountain View Pharmaceuticals Grants Worldwide License for a Long-Acting Protein  May 12, 2005 Savient Reports Positive Top-Line Results for Phase 2 Trial May 4, 2005 Mountain View Pharmaceuticals Elects Raymond J. Land to Its Board of Directors January 19, 2005 Mountain View Pharmaceuticals Grants Worldwide License for Long-Acting Multiple Sclerosis Drug January 10, 2005 Savient Pharmaceuticals, Inc. Completes Patient Dosing in Phase II Clinical Trial of Puricase for Severe Gout July 7, 2003 Savient Pharmaceuticals, Inc. Successfully Completes Phase I Clinical Study of Puricase® for Severe Gout August 17, 1998 Bio-Technology General Acquires Rights to Technology for Important New Drug, PEG-Uricase, from Duke University and Mountain View Pharmaceuticals, Inc.